| Uveitis
Iluvien vs Rayos
Side-by-side clinical, coverage, and cost comparison for uveitis.Deep comparison between: Iluvien vs Rayos with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsRayos has a higher rate of injection site reactions vs Iluvien based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Rayos but not Iluvien, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Iluvien
Rayos
At A Glance
Intravitreal injection
Corticosteroid
Oral
Daily
Corticosteroid
Indications
- Diabetic Retinopathy
- Uveitis
- Dermatitis, Atopic
- Allergic rhinitis (disorder)
- Serum Sickness
- Dermatitis Herpetiformis
- Contact Dermatitis
- Exfoliative dermatitis
- Mycosis Fungoides
- Pemphigus
- Erythema Multiforme
- Congenital Adrenal Hyperplasia
- Hypercalcemia
- thyroiditis; nonsuppurative
- Adrenal gland hypofunction
- Crohn Disease
- Ulcerative Colitis
- Autoimmune hemolytic anemia
- Anemia, Diamond-Blackfan
- Immune thrombocytopenic purpura
- Pure Red-Cell Aplasia
- Acute leukemia
- Lymphoma, Non-Hodgkin
- Multiple Sclerosis
- Cerebral Edema
- Ophthalmia, Sympathetic
- Uveitis
- Chronic Obstructive Airway Disease
- Aspergillosis, Allergic Bronchopulmonary
- Aspiration pneumonitis
- Asthma
- Tuberculosis
- Extrinsic allergic alveolitis
- Bronchiolitis Obliterans Organizing Pneumonia
- Idiopathic eosinophilic pneumonitis
- Idiopathic Pulmonary Fibrosis
- Pneumonia, Lipid
- Sarcoidosis
- Nephrotic Syndrome
- Primary gout
- Ankylosing spondylitis
- Dermatomyositis
- Polymyalgia Rheumatica
- Arthritis, Psoriatic
- Polychondritis, Relapsing
- Rheumatoid Arthritis
- Sjogren's Syndrome
- Lupus Erythematosus, Systemic
- Vasculitis
- Trichinellosis
- Tuberculosis, Meningeal
Dosing
Diabetic Retinopathy, Uveitis Single 0.19 mg (190 mcg) fluocinolone acetonide intravitreal implant injected under aseptic conditions via a preloaded single-use applicator; optimal placement is inferior to the optic disc and posterior to the equator, with needle entry 4 mm inferotemporal from the limbus.
All indications Initial dose 5-60 mg once daily with food; RAYOS releases active substance approximately 4 hours after intake. Titrate to lowest effective maintenance dose; withdraw gradually after long-term or high-dose therapy.
Contraindications
- Active or suspected ocular or periocular infections, including active epithelial herpes simplex keratitis (dendritic keratitis), vaccinia, varicella, mycobacterial infections, and fungal diseases
- Glaucoma with cup to disc ratio greater than 0.8
- Known hypersensitivity to any components of ILUVIEN
- Known hypersensitivity to prednisone or any excipient
Adverse Reactions
Most common (>=1%) Cataract, increased intraocular pressure, myodesopsia, eye pain, conjunctival haemorrhage, posterior capsule opacification, eye irritation, vitreous detachment, conjunctivitis, corneal oedema, ocular hyperaemia, anemia, headache, renal failure, pneumonia
Serious Optic nerve damage, visual acuity and field defects, secondary ocular infections including herpes simplex, perforation of the globe where there is thinning of the cornea or sclera
Postmarketing Drug administration error, drug ineffectiveness
Most common Fluid retention, altered glucose tolerance, elevated blood pressure, behavioral and mood changes, increased appetite and weight gain
Serious Anaphylaxis, cardiac arrest, circulatory collapse, congestive heart failure, myocardial rupture, pulmonary edema, peptic ulcer with perforation and hemorrhage, osteonecrosis, pathologic fracture, adrenocortical insufficiency, convulsions, increased intracranial pressure
Postmarketing No new safety concerns identified beyond those established for immediate-release prednisone
Pharmacology
Fluocinolone acetonide is a synthetic corticosteroid that inhibits inflammatory responses by blocking phospholipase A2 via lipocortins, suppressing biosynthesis of prostaglandins and leukotrienes and reducing edema, leukocyte migration, capillary proliferation, and fibroblast proliferation.
Prednisone is a synthetic corticosteroid with potent anti-inflammatory and immunosuppressive properties that suppresses inflammatory processes (edema, capillary dilatation, leukocyte migration), modifies immune responses, and produces metabolic effects including promotion of gluconeogenesis, protein catabolism, and altered calcium and electrolyte balance.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Iluvien
- Covered on 5 commercial plans
- PA (9/12) · Step Therapy (9/12) · Qty limit (0/12)
Rayos
- Covered on 5 commercial plans
- PA (6/12) · Step Therapy (1/12) · Qty limit (0/12)
UnitedHealthcare
Iluvien
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (0/8)
Rayos
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (0/8)
Humana
Iluvien
- Covered on 0 commercial plans
- PA (1/3) · Step Therapy (0/3) · Qty limit (0/3)
Rayos
- Covered on 0 commercial plans
- PA (1/3) · Step Therapy (0/3) · Qty limit (0/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
$25
Iluvien CoPay ProgramCommercial or private insurance
Medicare, Medicaid, VA, TRICARE
No savings programs available for Rayos.
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
IluvienView full Iluvien profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.